
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's operational sales growth reached 11.5% in the fourth quarter of 2025, even after considering a significant competitive headwind from generics on Stelara. The company's total revenue estimate for 2026 has been raised to $100.42 billion, supported by strong performances from key products like Tremfya and Rybrevant, indicating robust growth prospects. With impressive stock performance and a favorable outlook following 4Q results, JNJ demonstrates strong fundamentals poised for continued upward momentum.
Bears say
Johnson & Johnson faces significant risks that contribute to a negative outlook for its stock, particularly relating to the potential for rapid sales declines following the loss of patent exclusivity for key products, which could allow generics and biosimilars to capture market share. Disappointing launches of new medications, concerns surrounding macroeconomic factors such as U.S. drug pricing reform, and litigation risks associated with ongoing talc-related lawsuits could further pressure sales and earnings forecasts. Additionally, the failure of crucial pipeline assets, including posdinemab, amplifies uncertainty regarding future revenue streams, leading to heightened volatility in the company’s stock performance.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares